Bifurcation Lesions Market Size, Share & Trends Analysis Report By Application (Coronary Vascular, Peripheral Vascular), By Region (North America, Asia Pacific, Europe), And Segment Forecasts, 2023 - 2030

Report Overview

The global bifurcation lesions market size was estimated at USD 2.2 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2030. The market is driven by the increasing prevalence of coronary artery disease (CAD), the approval & commercialization of innovative devices, increased insurance coverage for bifurcation lesion procedures, and improved imaging modalities. According to the Centers for Disease Control and Prevention, CAD is the most common heart disease, which killed over 375,000 people in 2021. Furthermore, ongoing clinical trials on stents & balloons for the treatment of bifurcation lesions and an increase in the incidence of these lesions are likely to boost the market growth in the coming years.

Advancements in devices used in imaging and procedures along with a rise in the number of skilled surgeons have decreased associated risks, and this is likely to propel the market growth. Bifurcation lesions are coronary artery diseases that occur when plaque builds up in the arteries near the point where they branch off. This can cause narrowing of the arteries and reduce blood circulation to the heart. Bifurcation lesions are more difficult to treat than single lesions and are associated with a higher risk of complications, such as heart attack and stroke. People aged 60 years and above are more prone to heart attacks, strokes, coronary heart diseases & heart failure as compared to younger people.

In these cases, bifurcation lesions facilitate the treatment of blood clots to pump adequate blood to the heart. According to a report published in September 2020 by the United Nations Department of Economic and Social Affairs, the population aged 65 and over is projected to rise from 9.3% in 2020 to around 16.0% in 2050. In addition, according to a factsheet published by the World Health Organization (WHO) in October 2021, there were 1 billion people over the age of 60 in 2020 & the count is expected to increase to 1.4 billion by 2030. Therefore, an increasing geriatric population is expected to drive the market growth in the coming years. Continuous advancements in medical device technology, including innovative stent designs and imaging techniques, enhance the precision and effectiveness of bifurcation lesion interventions.

The shift toward minimally invasive procedures has increased the adoption of bifurcation lesion treatments, as they offer reduced procedural risks, shorter hospital stays, and faster recovery. The aging population is more prone to cardiovascular diseases, leading to an increased demand for bifurcation lesion interventions. Techniques, such as analysis, exposure to X-rays, the length of the treatment, as well as long-term follow-up are employed in its treatment. Three-dimensional (3D) angiography & multi-slice computing tomography are also employed to measure the bifurcation angles. Imaging, bifurcation stenting techniques, supplemental drugs & vascular access developments have made it possible to treat bifurcation lesions in challenging situations on a global scale.

Improvements in imaging modalities along with the growth of insurance coverage for treating bifurcation lesions are driving up the demand for bifurcation lesion procedures. For instance, Advanced Bifurcation Systems (ABS), a clinical-stage medical device company, has a platform with the only modular self-aligning stent technology to structure bifurcations. ABS has a unique bifurcation stenting solution to standardize the treatment of all bifurcation lesions in coronary angioplasties. The ABS platform is a one-of-a-kind device that eliminates the need for additional surgeries and makes bifurcation stenting treatment possible.

Application Insights

Based on the application, the market is further segmented into peripheral vascular and coronary vascular. In 2022, coronary vascular accounted for the largest market share of 69.8% due to the increased awareness, availability of dedicated products for coronary bifurcation lesions (CBLs), and a rise in percutaneous coronary intervention procedures. According to an article published in March 2022 in the World Journal of Cardiology, 15-20% of all percutaneous coronary procedures are for CBLs due to their technical complexity & low procedural success. The coronary vascular segment is expected to maintain its dominance during the forecast period due to ongoing clinical trials along with investments by key players.

This is likely to result in the introduction of new products and widen the application of existing products for bifurcation lesions. The peripheral vascular segment is likely to witness the fastest CAGR of 6.5% during the forecast period. This can be attributed to the growing awareness about Peripheral Arterial Diseases (PAD) and their rising incidence. According to the National Institute of Health, one in every 20 Americans aged over 50 years suffer from PAD, and it affects around 8 - 12 million people in the U.S. The deployment of stents is difficult in smaller peripheral arteries, hence, they cannot be used to treat PAD. Thus, angioplasty is preferred for its treatment. However, stent implantation is generally preferred over balloon angioplasty for the treatment of bifurcation lesions.

Regional Insights

North America dominated the global market in 2022 with the largest revenue share of 39.7% and is expected to maintain its dominance over the forecast period. This can be attributed to the local presence of major market players, higher disposable income, rise in demand for drug-eluting stents (DES) & favorable reimbursement policies. Europe accounted for the second-largest share of 28.8% in 2022 due to the presence of key industry players and government initiatives to improve healthcare access. In April 2023, Terumo Europe N.V., a medical device company, announced the start of a clinical study, the Ultimaster Nagomi.

To investigate new coronary stents in complex percutaneous coronary intervention (PCI). In November 2022, Ultimaster Nagomi received CE mark approval and is the next iteration of Terumo’s Ultimaster family stents. The Asia Pacific region is anticipated to witness the fastest CAGR of 6.8% during the forecast period due to an increase in the geriatric population and rising obesity cases, which have resulted in a high incidence of coronary heart diseases. Furthermore, a rise in awareness, adoption of newer technologies, approval of various balloons, and entry of international & new regional players are also expected to boost the regional market growth.

Key Companies & Market Share Insights

The market is highly competitive with players undertaking strategies, such as mergers & acquisitions and product launches & approvals, to gain market share. In 2022, Medtronic became the first company that receive FDA approval for a drug-eluting stent for PCI. The approval covers Resolute Onyx and Onyx to treat lesions that occurred with plaque accumulation in a major coronary artery division. Some of the major participants in the global bifurcation lesions market:

• Boston Scientific Corp.

• Abbott

• Cardinal Health

• Medtronic

• C. R. Bard, Inc.

• Johnson & Johnson Services, Inc.

• Spectranetics

• Terumo Medical Corp.

• Tryton Medical Inc.

Bifurcation Lesions Market Report Scope

Global Bifurcation Lesions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global bifurcation lesions market report on the basis of application, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Peripheral

  • Coronary

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait